MOH Arranges Centralized Drug Purchase Work
This article was originally published in PharmAsia News
Executive Summary
At a working meeting for national centralized drug purchase, Ministry of Health Deputy Minister Gao Qiang pointed out that such a system is the objective requirement of deepening the health care system reform and plays an important role. Centralized purchase will: improve the channels for ensuring drug supply as a centralized tender and competitive bidding process can increase drug purchase efficiency and effective supervision of unreasonable pricing; facilitate the establishment of a reasonable drug-price formulation mechanism; and promote pharmaceutical industry optimization and upgrades. Drug companies may redeploy marketing resources in good product development, quality enhancement and competitive building. (Click here for more - Chinese Language)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.